|
|
Varunamn |
|
|
Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare
|
Idacrybin |
Mexiko |
Idamen |
Turkiet |
Idamycin |
Förenta Staterna, Kanada, Mexiko |
Idaralem |
Colombia, Mexiko |
Ondarubin |
Mexiko |
Rubix |
Mexiko |
Zavedos |
Argentina, Australien, Belgien, Chile, Colombia, Danmark, Ecuador, Finland, Frankrike, Grekland, Irland, Island, Italien, Kroatien, Luxemburg, Malaysia, Marocko, Nederländerna, Norge, nya Zeeland, Österrike, Polen, Portugal, Rumänien, ryska, Saudi-Arabien, Schweiz, Slovenien, Spanien, Storbritannien, Sverige, Sydafrikanska republiken, Thailand, Tyskland, Ungern, Venezuela |
|
|
|
|
Hänvisningar : Idarubicin hydrochloride |
|
|
Typ |
Publikation |
3 |
tidningen |
Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
81 |
tidningen |
Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678. |
84 |
tidningen |
Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
99 |
tidningen |
Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
169 |
tidningen |
Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
182 |
tidningen |
Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60. |
244 |
tidningen |
Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
249 |
tidningen |
Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
307 |
tidningen |
Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
335 |
tidningen |
Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
491 |
tidningen |
Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184. |
632 |
tidningen |
Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222. |
905 |
tidningen |
Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
1410 |
tidningen |
Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
1423 |
tidningen |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1496 |
tidningen |
Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428. |
3474 |
Laboratorium |
Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009 |
3526 |
Laboratorium |
Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010 |
3595 |
Laboratorium |
Aciclovir - Summary of Product Characteristics Hospira 2009 |
3637 |
Laboratorium |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics Hameln Pharmaceuticals 2014 |
4661 |
tidningen |
Bourcier B, Lagarce R, Lebreton V. Stability of a high-concentrated aqueous solution of idarubicin stored in a polypropylene syringe for transarterial chemoembolization J Pharm Biomed Anal 2022 |
|
|